Change in the Board of Directors of Egetis Therapeutics
Stockholm, Sweden, October 4, 2024. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), today announced that Peder Walberg has decided to resign from the Board of Directors with immediate effect, to focus on his role as a major shareholder of the Company. Peder will continue to support the Company in his current operational role as a consultant to the Company.
Mats Blom, Chairman of the Board of Directors, said: “I would like to thank Peder for his invaluable contributions to the Board of Egetis and I’m pleased that he will continue to support the Company as a major shareholder and consultant.”
For further information, please contact:
Mats Blom, Chairman of the Board of Directors
+46 761 45 70 90